Author

N. E. Sealover

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:drug response / drug discovery· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

R. L. Kortum· 5 shared A. J. Linke· 3 shared B. R. Daley· 3 shared J. M. Hughes· 3 shared P. L. Theard· 3 shared E. Sheffels· 2 shared K. Cox· 2 shared A. Frank· 1 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

R. L. Kortum

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma

B. R. Daley, N. E. Sealover, E. Sheffels, J. M. Hughes, D. Gerlach, M. H. Hofmann, K. Kostyrko, B. Mair, A. Linke, Z. Beckley, A. Frank, C. L. Dalgard, R. L. Kortum

This study shows that SOS1 inhibition with BI-3406 enhances G12C inhibitor efficacy and delays resistance in lung adenocarcinoma by targeting resistance mechanisms and drug-tolerant persister cells.

bioRxiv · Dec 7, 2023 · PreprintCancer Biology

In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies

N. E. Sealover, P. L. Theard, J. M. Hughes, A. J. Linke, B. R. Daley, R. L. Kortum

This paper introduces an in situ resistance assay to model acquired resistance to RTK/RAS pathway targeted therapies and shows SHP2 inhibitors can delay resistance development.

bioRxiv · Jan 27, 2023Cancer Biology

SOS2 regulates the threshold of mutant EGFR-dependent oncogenesis

P. L. Theard, A. J. Linke, N. E. Sealover, B. R. Daley, J. Yang, K. Cox, R. L. Kortum

This study shows SOS2 modulates EGFR-PI3K signaling threshold, affecting osimertinib efficacy and resistance in lung adenocarcinoma.

bioRxiv · Jan 20, 2023Cancer Biology

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status

B. Daley, H. M. Vieira, C. Rao, J. M. Hughes, Z. M. Beckley, D. H. Huisman, D. Chatterjee, N. E. Sealover, K. Cox, J. W. Askew, R. A. Svoboda, K. W. Fisher, R. E. Lewis, R. L. Kortum

This study shows that targeting SOS1 or KSR1 enhances MEK inhibitor efficacy and prevents resistance in KRAS-mutated cancers, depending on specific KRAS and co-mutation status.

bioRxiv · Dec 6, 2022Cancer Biology

Marked Synergy by Vertical Inhibition of EGFR signaling in NSCLC Spheroids: SOS1 as a therapeutic target in EGFR-mutated cancer

P. L. Theard, E. Sheffels, N. E. Sealover, A. J. Linke, D. J. Pratico, R. L. Kortum

The paper shows that inhibiting SOS1 synergizes with EGFR-TKIs in 3D spheroids of EGFR-mutated NSCLC, enhancing signaling pathway inhibition.

bioRxiv · Apr 28, 2020Cancer Biology